Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

LEO Pharma acquires Tanabe Pharma's dersimelagon for rare photosensitivity diseases in $435M deal
Acquisition, rare disease, small molecule, milestone payments, royalties - Read more

GSK takes exclusive global license to Chugai Pharmaceutical's anti-dengue antibody AID351, royalties eligible
Licensing deal, infectious disease, antibody, royalties - Read more

Evaxion collaborates with Duke University School of Medicine on EVX-05, AI-designed off-the-shelf glioblastoma vaccine
Research collaboration, oncology, AI/ML, vaccine, drug discovery - Read more

Biokin Pharma's (iza-bren) EGFRxHER3 bispecific ADC meets Ph3 primary endpoint in EGFR-mutated nonsquamous non-small cell lung cancer
Antibody-drug conjugate, cancer, bispecific ADC, non-small cell lung cancer, EGFR mutation, HER3 - Read more

Amylyx Pharmaceuticals eyes FDA filing for (avexitide) after Ph3 win in post-bariatric hypoglycemia
Small molecule, metabolic, GLP-1 antagonist, post-bariatric hypoglycemia, avexitide - Read more

Tcelltech's B7-H3-targeting CAR-T cell therapy shows Ph1 promise in recurrent glioblastoma
Cell therapy, cancer, CAR-T, glioblastoma, B7-H3 target, blood-brain barrier - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Craif raises $33M Series D to advance urine-based cancer detection U.S. expansion
Cancer diagnostics, AI/ML platform, microRNA, liquid biopsy, pancreatic cancer - Read more

Zentalis Pharmaceuticals raises $92.6M public offering, advancing WEE1 inhibitor azenosertib for ovarian cancer
Oncology, small molecule, WEE1 inhibitor, biomarker-driven, clinical-stage, ovarian cancer - Read more

Leal Therapeutics raises $30M Series A extension, advancing neuro-metabolic therapeutics for schizophrenia and ALS
Neurological, small molecule, clinical-stage, schizophrenia, ALS - Read more

Eurofins CDMO Alphora expands Mississauga facility to meet growing high-potency API manufacturing demand
High-potency API, ADC, operational, CDMO - Read more

BioMarin Pharmaceutical acquires Alesta Therapeutics for $275M to challenge AstraZeneca in rare bone disease market
Small molecule, rare disease, major transaction, strategic, competitive - Read more

Rigel Pharmaceuticals launches Veppanu (vepdegestrant), first FDA-approved PROTAC, for estrogen receptor-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer
Small molecule, cancer, PROTAC, breast cancer, ESR1 mutation, estrogen receptor degrader - Read more

Johnson & Johnson MedTech secures FDA clearance for Monarch Quest 3 software update enhancing lung cancer detection
Robotic surgery, oncology, regulatory, operational - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Regeneron discontinues Ph1/2 trial of REGN7041 (anti-CD3 antibody) for non-infectious uveitis over safety concerns
Antibody, autoimmune, monoclonal antibody, uveitis, CD3 target - Read more

Sanofi lays off 229 Blueprint Medicines staff, closes Cambridge offices post-$9.1B acquisition integration
Small molecule, rare disease, cost reduction, operational - Read more

Merck KGaA's EMD Serono cuts 20 staff at Billerica site amid broader R&D restructuring
Operational, R&D, cost reduction, strategic - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here